Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p75
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 75/162)
Character Range: 15054260–15060103

co-administered with an ACE inhibitor or an angiotensin II antagonist.
C14255              P14255         CN14255          Candesartan with hydrochlorothiazide                 Hypertension
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                    Irbesartan with hydrochlorothiazide                  The treatment must not be for the initiation of anti-hypertensive therapy; AND
                                                                                                         The condition must be inadequately controlled with an angiotensin II antagonist.  or
                                                    Olmesartan with hydrochlorothiazide                  The condition must be inadequately controlled with a thiazide diuretic.

                                                    Telmisartan with hydrochlorothiazide

                                                    Valsartan with hydrochlorothiazide

C14257              P14257         CN14257          Amlodipine with valsartan                            Hypertension
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                    Olmesartan with amlodipine                           The treatment must not be for the initiation of anti-hypertensive therapy; AND
                                                                                                         The condition must be inadequately controlled with an angiotensin II antagonist.  or
                                                    Telmisartan with amlodipine                          The condition must be inadequately controlled with a dihydropyridine calcium channel blocker.

C14259              P14259         CN14259          Calcitriol                                           Established osteoporosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 14259
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                         Patient must have fracture due to minimal trauma.
                                                                                                         The fracture must have been demonstrated radiologically and the year of plain x-ray or computed tomography (CT) scan or magnetic resonance imaging (MRI) scan must be documented in the patient's medical records when treatment is initiated.
                                                                                                         A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
C14260              P14260         CN14260          Mesalazine                                           Ulcerative colitis
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
C14263              P14263         CN14263          Risedronic acid                                      Established osteoporosis
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                         Patient must have fracture due to minimal trauma; AND
                                                                                                         Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition.
                                                                                                         The fracture must have been demonstrated radiologically and the year of plain x-ray or computed tomography (CT) scan or magnetic resonance imaging (MRI) scan must be documented in the patient's medical records when treatment is initiated.
                                                                                                         A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights